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Abstract
Background: In the present study, we aimed to investigate the effect of counteracting inhibitor of apoptosis (IAP)
proteins using the small molecule Second Mitochondria-derived Activator of Caspase (SMAC) mimetic BV6 in
combination with ionizing radiation on apoptosis, cell cycle regulation, DNA double-strand break (DSB) repair,
three-dimensional (3D) clonogenic survival and expression of IAPs in colorectal carcinoma cells.
Material and methods: Colorectal cancer cell lines (HCT-15, HT-29, SW480) were subjected to BV6 treatment (0–4 μM)
with or without irradiation (2–8 Gy, single dose) followed by MTT, Caspase 3/7 activity, γH2AX/53BP1 foci assays,
AnnexinV staining, cell cycle analysis, 3D colony forming assays and Western blotting (cellular IAP1 (cIAP1) and cIAP2,
Survivin, X-linked IAP (XIAP)).
Results: BV6 treatment decreased cell viability and significantly increased irradiation-induced apoptosis as analyzed by
Caspase 3/7 activity, AnnexinV-positive and subG1 phase cells. While basal 3D clonogenic survival was decreased in a
cell line-dependent manner, BV6 significantly enhanced cellular radiosensitivity of all cell lines in a concentration-
dependent manner and increased the number of radiation-induced γH2AX/53BP1-positive foci. Western blot analysis
revealed a markedly reduced cIAP1 expression at 4 h after BV6 treatment in all cell lines, a substantial reduction of XIAP
expression in SW480 and HT-29 cells at 24 h and a slightly decreased cIAP2 expression in HCT-15 cells at 48 h after
treatment. Moreover, single or double knockdown of cIAP1 and XIAP resulted in significantly increased residual γH2AX/
53BP1-positive foci 24 h after 2 Gy and radiosensitization relative to control small interfering RNA (siRNA)-treated cells.
Conclusion: The SMAC mimetic BV6 induced apoptosis and hampered DNA damage repair to radiosensitize 3D
grown colorectal cancer cells. Our results demonstrate IAP targeting as a promising strategy to counteract radiation
resistance of colorectal cancer cells.
Background
Colorectal carcinoma is the third most prevalent cancer
and constitutes the fourth most common cause of cancer-
related death worldwide [1]. Since publication of the first
results of the CAO/ARO/AIO-94 study, preoperative
radiochemotherapy provides the standard treatment of
locally advanced rectal cancer [2, 3]. However, tumor
cells frequently develop strategies to escape cell death
upon radio- and/or chemotherapeutic treatment which
interferes with efficient treatment of the patients. To over-
come therapeutic limitations, efforts have been made to
identify factors resulting in a therapy resistance and to tar-
get those factors, which may improve clinical outcome [4].
In this context, members of the inhibitor of apoptosis
(IAP) protein family recently gained attention as attractive
target molecules for sensitizing tumor cells to radiation
therapy [5, 6]. Currently, eight different IAPs are known
in mammals. Amongst them, Survivin has been exten-
sively studied because of its multiple functions which
comprise not only inhibition of Caspases and apoptosis
but also regulation of cell division as part of the chromo-
somal passenger complex and radiation-induced damage
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repair [7–9]. Notably, overexpression of Survivin and a sec-
ond well-studied member of this protein family, X-linked
IAP (XIAP), is associated with a resistant phenotype in
advanced rectal cancer after preoperative radiochemother-
apy marked by increased local failure rates, distant metasta-
sis and decreased overall survival [10, 11].
A common structural feature of IAPs is their baculo-
virus IAP repeat (BIR) domain, present in different num-
bers in all IAPs and required for apoptosis inhibition [12].
This structural domain is responsible for multiple protein
interactions and regulation of IAP function. For Caspase
inhibition, interaction of Survivin with XIAP by their BIR
domains and with hepatitis B X-interacting protein
(HBXIP) has been shown to be essential, while direct
binding to Caspases 3, 7 and 9 is only mediated by XIAP
[13, 14]. The carboxy-terminal Really Interesting New
Gene (RING) domain, present for example in cellular
IAP1 (cIAP1), cIAP2 and XIAP, functions as an E3 ubiqui-
tin ligase and promotes ubiquitination and subsequent
proteasomal degradation of the respective IAP and some
of their binding partners [15, 16].
Amongst various IAP targeting approaches developed
during the last years, substances mimicking the binding
motif of the IAP antagonist Second Mitochondria-derived
Activator of Caspase (SMAC) have gained growing atten-
tion. SMAC is released from mitochondria into the cyto-
sol upon the induction of the intrinsic apoptosis pathway
to negatively regulate IAP activity by binding to the BIR
domains [17, 18]. The interaction between SMAC and
XIAP, for example, prevents interaction of XIAP with Cas-
pase 9 and subsequent activation of the apoptotic pathway
[13]. Although the functions of cIAP1 and cIAP2 are less
clear compared to XIAP and Survivin, it has been shown
that both can function as E3 ubiquitin ligases and contrib-
ute to regulation of canonical and non-canonical nuclear
factor kappa B (NF-κB) signaling pathways and are
involved in the upregulation of cytotoxic cytokines like
tumor necrosis factor-alpha (TNF-α) [15]. The latter ren-
ders human cancer cells susceptible to apoptosis induction
in an autocrine/paracrine manner [19].
The bivalent SMAC mimetic BV6 binds to the BIR do-
mains of IAP proteins, causing ubiquitination and protea-
somal degradation of cIAPs and prevents XIAP-mediated
Caspase inhibition leading to apoptosis induction as single
agent treatment. Its therapeutic potential, however, is en-
hanced when combined with additional anticancer agents
or ionizing irradiation [20–22]. In terms of combination
with ionizing radiation, own previous data showed potent
and concentration-dependent BV6-mediated radiosensiti-
zation of a panel of glioblastoma cell lines in a conven-
tional two-dimensional (2D) colony formation assay [23].
In the present study, we aimed to examine cytotoxicity,
apoptosis, cell cycle distribution, expression of IAPs
Survivin, cIAP1, cIAP2 and XIAP and used the more
physiologic three-dimensional (3D) clonogenic survival
assay in three colorectal cancer cell lines, pretreated with
BV6 followed by exposure to different doses of ionizing
radiation. In the above mentioned studies the contribution
of SMAC mimetics to apoptosis-induced cell death was
the main focus, in the present study we also aimed to
analyze the impact of BV6 on radiation-induced DNA




Human colorectal carcinoma cell lines SW480, HT-29
and HCT-15 were selected according to their intrinsic
radiation sensitivity and obtained from the American Type
Culture Collection (LGC-Promochem, Wiesbaden,
Germany). SW480 is homozygous for p53 mutation Arg-
273→His and Pro-309→Ser. HT-29 cells also carry the
homozygous mutation Arg-273→His, while the HCT-15
cell line is heterozygous for p53 mutation Pro-153→Ala
[24–26]. Cells were cultured in DMEM (SW480; Life
Technologies, Darmstadt, Germany), McCoy’s 5A modi-
fied (HT-29; Biochrom, Berlin, Germany) or RPMI
medium (HCT-15; Life Technologies), supplemented with
10 % fetal calf serum (PAA, Cölbe, Germany) and 50 U/
ml penicillin and 50 μg/ml streptomycin (Sigma-Aldrich,
Munich, Germany) at 37 °C, 5 % CO2 and 95 % humidity.
BV6 treatment and irradiation procedure
The bivalent SMAC mimetic BV6 was kindly provided by
Genentech Inc. (South San Francisco, CA, USA) [15].
Cells were treated with 0.1–4 μM BV6 as indicated or with
equivalent amounts of the solvent dimethyl sulfoxide
(DMSO; AppliChem, Darmstadt, Germany) 4 h before ir-
radiation. Irradiation with single doses of 2–8 Gy was per-
formed using a linear accelerator (SL-15, Elekta, Crawley,
UK) with 6 MeV/100 cm focus-surface distance and a
dose rate of 4 Gy/min.
MTT assay
Cells were plated at a density of 1 × 103 cells per 200 μl in
a 96-well microplate, grown for 24 h and subsequently
treated with 1 or 4 μM BV6 or DMSO 4 h before irradi-
ation with indicated doses. After an additional 24 h of
incubation at 37 °C and 5 % CO2, 3-(4,5-Methylthiazol-2-
yl)-2,5-diphenyl-tetrazolium bromide (MTT, Applichem)
was added (20 μl/well of a 5 mg/ml solution in phosphate
buffered saline (PBS, Life Technologies)) for 4 h.
Solubilization of the converted purple formazan dye was
accomplished by adding 50 μl of 0.01 N HCl/20 % SDS per
well and incubation overnight at 37 °C. The reaction prod-
uct was quantified by measuring the absorbance at 570 nm
using a microplate reader (Wallac VICTOR 1420, PerkinEl-
mer, Waltham, USA).
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Caspase 3/7 assay, AnnexinV detection of apoptosis and
flow cytometric analysis
Cells were treated with BV6 (0.1–4 μM) or DMSO control
4 h before irradiation. At 24 h after irradiation, Caspase 3/
7 activity, AnnexinV-positive cells or cell cycle distribution
was measured to determine apoptosis induction. For
quantification of Caspase 3/7 activity, a CASPASE GLO™-
assay (Promega, Mannheim, Germany) was used accord-
ing to the manufacturer’s instructions and luminescence
was measured with a Wallac VICTOR microplate reader.
For detection of AnnexinV-positive cells, cells were har-
vested, washed with PBS and stained with Annexin-V-
Fluos labeling solution (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s protocol. For
analysis of cells in subG1, G1, S or G2/M phase of cell
cycle, non-irradiated cells were collected by trypsinization,
washed with PBS, fixed and stained with a solution con-
taining 40 μg/ml propidium iodide (Sigma-Aldrich) and
40 μg/ml RNaseA (Qiagen, Hilden, Germany). Quantifica-
tion of AnnexinV-positive, subG1, G1, S and G2/M phase
cells was performed with a FACSCalibur flow cytometer
(Becton Dickinson, Heidelberg, Germany) and Cellquest
Pro software (Becton Dickinson).
Small interfering RNA (siRNA)-mediated knockdown of
cIAP1 and XIAP
The human cIAP1-specific siRNA was obtained from
Eurofins Genomics (Ebersberg, Germany): cIAP1 siRNA:
5′-GGCCAAGAGUUUGUUGAUtt-3′ (sense) [27]. The
human XIAP siRNA was obtained from Applied Biosys-
tems (Darmstadt, Germany): 5′- GCAGAUUUAUCAA
CGGCUUtt-3′, siRNA ID s1456 [28]. A non-specific
negative control siRNA was obtained from Qiagen
(Hilden, Germany). siRNA transfection was performed
at a total concentration of 40 nM control siRNA. For sin-
gle cIAP1 or XIAP knockdown conditions, 20 nM specific
siRNA was complemented with 20 nM control siRNA to
achieve a total siRNA concentration of 40 nM. Double
knockdown experiments were carried out using 20 nM
cIAP1 and 20 nM XIAP siRNA. Cells were transfected
with Roti-Fect PLUS reagent according to the manufac-
turer’s instructions (Roth, Karlsruhe, Germany).
Immunofluorescence staining and quantification of
γH2AX and 53BP1 foci formation
DNA double-strand breaks (DSB) were analyzed by count-
ing of γH2AX- and 53BP1-positive nuclear foci as previ-
ously described [29]. In brief, colorectal carcinoma cells
were cultured on 8-well slides (BD Falcon, Heidelberg,
Germany), siRNA-transfected and irradiated 24 h there-
after or treated with DMSO, 1 μM or 4 μM BV6 and
irradiated 4 h thereafter with a dose of 2 Gy. Subse-
quently, cells were fixed after indicated time points
with either ice-cold methanol in case of γH2AX
detection or 3.7 % paraformaldehyde in case of 53BP1 de-
tection. Permeabilization was performed by addition of
0.1 % of Triton X-100, followed by blocking with 5 %
BSA, 0.05 % Triton X-100, 1 μg/ml rabbit/mouse serum
and incubation with anti-γH2AX (clone JBW301, 05–636,
Millipore, Schwalbach, Germany) or anti-53BP1 (100–
304, Novus Biologicals, Cambridge, UK) primary anti-
bodies. Staining was accomplished by incubation with
appropriate Alexa-labeled secondary antibodies (Alexa
Fluor 594 goat anti-mouse, Alexa Fluor 488 goat anti-
rabbit, Life Technologies) and counterstaining of nuclei
with 4′,6-diamidino-2-phenylindole (DAPI) solution (Life
Technologies). Coverslips were mounted with Vectashield
mounting medium (Alexis, Grünberg, Germany). γH2AX-
and 53BP1-positive foci were microscopically counted
using an AxioImager Z1 microscope equipped with Axio-
Vision 4.6 software (Carl Zeiss, Göttingen, Germany) and
100–150 nuclei were evaluated for each data point from
three independent experiments. Fluorescence images were
obtained using the AxioImager Z1 microscope equipped
with AxioVision 4.6 software (Carl Zeiss).
3D colony formation assay
Measurement of 3D cell survival was accomplished as
described before [30, 31]. In brief, single cells were plated
into a mixture of 0.5 mg/ml laminin-rich extracellular
matrix (lrECM; Cultrex 3D Culture Matrix BME Reduced
Growth Factor Basement Membrane Extract; R&D Sys-
tems, Wiesbaden, Germany) in 96-well plates. After 24 h,
cells were treated with DMSO, 0.1, 0.25, 1 or 1.5 μM BV6
or left untreated (mock) and irradiated (2, 4, 6 Gy) 4 h
later. For cIAP1 and/or XIAP knockdown experiments,
cells were transfected with siRNA and plated 24 h there-
after into lrECM 3D matrix. Irradiation of cells with single
doses of 0, 2, 4, 6 Gy was performed 24 h after plating.
Colonies (>50 cells) were microscopically counted at least
6 days after plating, dependent on the cell line used.
Images from typical colony formation of colorectal cancer
cell lines were obtained using an AxioImager Z1 micro-
scope. Surviving fractions from 3D clonogenic assays were
calculated as follows: numbers of colonies formed/(num-
bers of cells plated (irradiated) × plating efficiency (non-ir-
radiated)). Each point on survival curves represents the
mean surviving fraction from at least three independent
experiments, each performed in quadruplicate. Survival
variables α and β were fitted according to the linear quad-
ratic equation (SF = exp [−α ×D − β ×D2] with D = dose
using EXCEL software (Microsoft, Redmond, USA).
Western blotting
Cells were plated in 0.5 mg/ml lrECM for 24 h, treated
either with DMSO or 1 μM BV6 4 h before irradiation
with 4 Gy and subjected to Western blotting at different
time points thereafter as reported before [30, 31]. The
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following primary antibodies were applied: anti-cIAP1
(AF8181, R&D Systems), anti-cIAP2 (1040–1, Abcam,
Cambridge, UK), anti-Survivin (AF886, R&D Systems),
anti-XIAP (BD610716, Becton Dickinson) and anti-β-
actin (A5441, Sigma-Aldrich). For detection, secondary
antibodies chicken anti-goat IgG HRP (sc-2953; Santa Cruz,
Heidelberg, Germany), goat anti-rabbit IgG HRP (sc-
2054; Santa Cruz), goat anti-mouse IgG HRP (sc-20559;
Santa Cruz), Pierce ECL Western Blotting Substrate
and Amersham Hyperfilm ECL (Thermo Fisher Scien-
tific, Waltham, USA) were used.
Data analysis
To test statistical significance, the two-sided unpaired
Student’s t-test was performed using EXCEL software
(Microsoft, Unterschleißheim, Germany). Results were
considered statistically significant if a p-value of less
than 0.05 was reached.
Results
To investigate potential cytotoxic effects of the SMAC mi-
metic BV6 alone or in combination with irradiation, a col-
orimetric MTT assay was applied. As shown in Fig. 1a, a
24 h BV6 treatment reduced SW480, HT-29 and HCT-15
colorectal cancer cell viability in a concentration- and cell
line-dependent manner with a significant reduction of via-
bility following sole BV6 treatment. This effect was further
enhanced by additional irradiation (2 or 8 Gy) at 4 h after
BV6 treatment, most pronounced in SW480 and HT-29
cells (Fig. 1a). Next, the impact of BV6 and irradiation on
apoptosis induction was evaluated by measurement of
Caspase 3/7 activity, detection of AnnexinV-positive cells
(Fig. 1) and determination of subG1 apoptotic cells (Fig. 2).
Treatment with BV6 substantially increased Caspase 3/7
activity (Fig. 1b) and the fraction of AnnexinV-positive
cells (Fig. 1c) 24 h after irradiation with a dose of 2 or
8 Gy. Moreover, BV6 application resulted in a significant
increase of the subG1 population of non-irradiated cells at
Fig. 1 Combined BV6 treatment and irradiation decreases cell viability and enhances apoptosis of colorectal carcinoma cells. SW480, HT-29 and
HCT-15 cells were treated with 1 μM or 4 μM BV6 or with DMSO as a control for 4 h and were subsequently irradiated with a dose of 0, 2 or
8 Gy. After 24 h, cells were subjected to a colorimetric MTT-assay (a), analysis of Caspase 3/7 activity (b) or flow cytometric measurement of
AnnexinV-positive cells (c). Results represent means ± SD (n = 3). Student’s t-test compared BV6-treated vs. DMSO-treated cells (*P <0.05;
**P <0.01)
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24 h (Fig. 2a) and 72 h (Fig. 2b) post BV6 treatment, while
cell cycle distribution and the fraction of cells in G1, S or
G2/M phase were not substantially altered by treatment
with the SMAC mimetic (Fig. 2a, b).
To investigate a potential impact of the drug on DNA
repair capacity, cells were next treated for 4 h with 1.0 or
4.0 μM BV6, irradiated with a dose of 2 Gy and subjected
to γH2AX or 53BP1 foci analysis at 0, 1, 6, 12 or 24 h after
irradiation. Both, γH2AX and 53BP1 radiation-induced
nuclear foci were significantly increased after 4 μM BV6
treatment as compared to DMSO controls, suggesting a
BV6-dependent modulation of DNA repair pathways in
SW480, HT-29 and HCT-15 colorectal cells (Fig. 3a, b
and Additional file 1: Figure S1).
For analysis of long term clonogenic survival, cells were
plated in a more physiologic 3D laminin-rich extracellular
matrix, treated with 0.1, 0.25, 1.0 or 1.5 μM BV6 and clo-
nogenic survival was microscopically evaluated 6–8 days
thereafter (Fig. 4a). Basal clonogenicity was concentra-
tion- and cell line-dependently decreased with the most
pronounced effect on HT-29 cells, demonstrated by a
70.8 % reduced survival after treatment with 1.5 μM
BV6. In contrast, HCT-15 responded only mildly to
BV6 treatment, while treatment of SW480 cells with
1.5 μM BV6 resulted in a medium response, illustrated
by a 54.8 % reduction of clonogenic survival (Fig. 4b).
When combined with ionizing radiation, BV6 pretreatment
resulted in a concentration-dependent radiosensitization in
all three lines investigated, again most pronounced in HT-
29 cells (Fig. 4c).
To test the effect of the SMAC mimetic in combination
with irradiation on the expression of several IAPs, West-
ern blot analyses were applied. As depicted in Fig. 5, we
observed a cell line-dependent degradation of IAP pro-
teins after BV6 exposure, while irradiation does only
marginally modulate cIAP1, cIAP2 or XIAP expression. In
detail, a treatment of SW480, HT-29 and HCT-15 cells
with 1 μM BV6 resulted in a rapid degradation of cIAP1
with non-detectable levels after a 4 h treatment in SW480
and HT-29 cells. XIAP was degraded at 24 h after BV6
exposure in SW480 and HT-29 cells, while HCT-15 cells
showed no effect. By contrast, cIAP2 and Survivin
Fig. 2 BV6 increases the fraction of colorectal cancer cells in subG1 phase. a – b Flow cytometric analysis of subG1, G1, S and G2/M phase
colorectal cancer cells at indicated time points after treatment with BV6 or DMSO control. Data are displayed as means ± SD from three
independent experiments. Asterisks indicate significant differences (*P <0.05; Student’s t-test) as compared to DMSO-treated controls
Hehlgans et al. Radiation Oncology  (2015) 10:198 Page 5 of 11
expression were only slightly affected by BV6 treatment,
with a moderate decreased expression at 48 h (cIAP2) and
120 h (cIAP2 and Survivin) in all cell lines.
To further confirm that a degradation of cIAP1 and
XIAP is correlated to a hampered DNA repair and clono-
genic survival upon irradiation, we performed siRNA-
mediated knockdown of cIAP1 and/or XIAP in SW480
and HCT-15 cells (Fig. 6a). Irradiation of single cIAP1 or
XIAP knockdown cell cultures significantly increased re-
sidual γH2AX- and 53BP1-positive foci 24 h after 2 Gy
relative to control siRNA-treated cells (Fig. 6b, c). Double
knockdown of cIAP1 and and XIAP, however, only mar-
ginally further increased the number of residual γH2AX
and 53BP1 foci in both SW480 and HCT-15 cells, indicat-
ing the involvement of common molecular pathways. In
line with that, 3D radiation survival was significantly re-
duced after cIAP1, XIAP and cIAP1/XIAP depletion
(Fig. 7a, c). The radiosensitization was most pronounced
following a cIAP1 and XIAP double knockdown while
basal clonogenic survival of non-irradiated cells was not
altered by different knockdown conditions (Fig. 7b).
Discussion
Evasion of apoptosis is a hallmark of cancer that contrib-
utes to tumorigenesis and tumor progression and displays
a major obstacle in the efficacy of anticancer treatment
such as radiation therapy [32]. Thus, interfering with the
apoptotic pathways by the development of small molecule
inhibitors that mimic the endogenous IAP inhibitory
protein SMAC may present a promising strategy to coun-
teract resistance. In the current study, we investigated the
effect of combined BV6 SMAC mimetic treatment and
ionizing radiation on cell viability, apoptosis, DNA repair
and 3D clonogenic survival of three colorectal cancer cell
lines. We found significantly enhanced effects in terms of
viability, apoptosis induction, clonogenic survival and
DNA damage repair after combined modality treatment
with BV6 and irradiation.
There is growing knowledge on the mechanisms of a
SMAC mimetic-mediated tumor cell sensitization that in-
clude increased caspase activation and engagement of an
autocrine cell death loop via NF-κB mediated TNF-α/
TNF receptor signaling [15, 19]. SMAC mimetics may
Fig. 3 Treatment with BV6 elevates irradiation-induced nuclear foci formation. SW480, HT-29 and HCT-15 colorectal carcinoma cell lines were
treated either with DMSO as a control or with 1 or 4 μM BV6 4 h before irradiation. Immunofluorescence staining for γH2AX (a) or 53BP1 (b)
was accomplished 0, 1, 6, 12 and 24 h after irradiation with 2 Gy and nuclear foci were counted subsequently (means ± SD; n = 3; * P <0.05;
Student’s t-test)
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Fig. 4 BV6 treatment decreases basal clonogenic survival and substantially radiosensitizes colorectal cancer cells. Single cells were plated in a 3D
extracellular matrix and 24 h thereafter, cells were treated either with DMSO or increasing concentrations of BV6 (0.1, 0.25, 1, 1.5 μM) or were left
untreated (mock). At 4 h after BV6 treatment, cells were irradiated with 0, 2, 4 or 6 Gy (single doses) and ≥6 days after plating colonies >50 cells
were microscopically counted. a Typical colony formation of DMSO- or BV6-treated colorectal cancer cell lines ≥6 days after plating (bar, 200 μm).
b Survival curves of indicated colorectal cancer cell lines after BV6 treatment were calculated and normalized to DMSO-treated cells (means ± SD;
n ≥3; *P <0.05; **P <0.01; Student’s t-test). c To evaluate 3D radiation survival, single cells were pretreated for 4 h with DMSO or increasing
concentrations of BV6 or left untreated (mock). Subsequently, cells were irradiated (0–6 Gy, single dose) and survival fractions relative to
non-irradiated controls were calculated. Curves were fitted according to the linear quadratic model (means ± SD; n ≥3; *P <0.05; **P <0.01;
Student’s t-test in comparison to DMSO-treated controls)
Fig. 5 BV6 considerably reduces expression of IAP proteins. SW480, HT-29 and HCT-15 cells were plated in a 3D laminin-rich extracellular matrix
and treated with 1 μM BV6 or DMSO control 4 h before irradiation with 4 Gy. At different time points, expression of indicated proteins was
analyzed by Western blotting, while β-actin served as loading control. Two independent experiments were performed with similar results
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further sensitize tumor cells to DNA damaging agents by
favouring the assembly of a cytosolic multi-protein
complex (Ripoptosome) containing receptor-interacting
serine/threonine protein kinase 1 (RIP1). This complex
signals cell death by stimulating NF-κB activation and
induction of a non-apoptotic form of programmed cell
death called necroptosis [33, 34]. Although not addressed
in the present study, radiation sensitization upon BV6
treatment in colorectal cancer lines may arise from mul-
tiple mechanisms including apoptosis, necroptosis and
mitotic catastrophe.
Indeed, radiation-induced cell death involves Caspase-
dependent and Caspase-independent mechanisms [35].
Especially in solid tumors, mitotic catastrophe upon irrep-
arable DNA damage is thought to constitute a mechanism
contributing to cell inactivation. Mitotic catastrophe often
occurs as a consequence of non-repaired DNA damage
and a deficiency in cell cycle checkpoints and frequently
results from the presence of mutated or inactivated p53
protein in tumor cells [36], which is the case in the cell
lines investigated in the present study. Notably, radiation
induced apoptosis upon XIAP knockdown is more
pronounced in p53 mutated lung carcinoma cells, indicat-
ing that XIAP-mediated sensitization might be more
effective in p53 mutated cells [37].
Since radiation sensitivity of cells varies considerably in
dependence of their cell cycle phase [38], we analyzed the
impact of BV6 on cell cycle distribution in non-irradiated
cells. While BV6 treatment increased the fraction of cells
in subG1 phase indicative of apoptosis in a time- and
concentration-dependent manner (Fig. 2), we did not
observe a significant impact of the BV6 mono substance
on the number of cells in G1, S or in G2/M phase, sug-
gesting that cell cycle regulation by BV6 treatment at the
time of irradiation might not contribute to increased radi-
ation response. Similar to our results, single BV6 treat-
ment of Panc1 pancreatic carcinoma cells did not result in
significant changes of G1, S or G2/M phases of the cell
cycle [39].
Concerning the BV6- and irradiation-mediated modula-
tion of IAP expression, we found a rapid degradation of
cIAP1 in all three cell lines and a slower decrease of XIAP
expression in two out of three cell lines. cIAP2 and
Survivin expression, by contrast, were only moderately
Fig. 6 cIAP1 and XIAP depletion hampers DNA double-strand break repair. SW480, and HCT-15 colorectal cancer cells were subjected to
siRNA-mediated cIAP1 and/or XIAP knockdown 48 h before irradiation. a Western Blot analysis confirmed knockdown of cIAP1 and XIAP (X) at
48 h after siRNA transfection, while β-actin served as loading control. Immunofluorescence staining for γH2AX (b) or 53BP1 (c) was accomplished
24 h after irradiation with 2 Gy and nuclear foci were counted subsequently (means ± SD; n = 3; * P <0.05; **P <0.01; Student’s t-test). Representative
photographs of indicated conditions show staining of nuclei in blue (DAPI), γH2AX in red and 53BP1 in green (scale bar, 5 μm)
Hehlgans et al. Radiation Oncology  (2015) 10:198 Page 8 of 11
decreased in all lines at 120 h after BV6 treatment. Our
observations are partly in line with previously published
studies, revealing rapid degradation of cIAP1 and cIAP2
and slower degradation of XIAP in MDA-MB-231 breast
carcinoma cells [15] or downregulation of cIAP1, cIAP2
and XIAP levels in MV4-11, OCI-AML3 and NB4 acute
myeloid leukemia cells [20, 22] upon BV6 treatment.
However, variances in cIAP2 degradation kinetics might
result from the use of different cell lines, BV6 concentra-
tions, time points and/or cell culture conditions (3D vs.
2D) used. Interestingly, SM-164 compound was shown to
decrease cIAP1 expression and to prevent XIAP binding
to caspases without affecting XIAP expression [40], fur-
ther stressing the point on a cancer line specific regulation
of IAPs upon SMAC mimetic treatment.
The impact of BV6 on clonogenic radiation survival was
evaluated under 3D cell culture conditions, which are
thought to mimic the in vivo situation more closely than
the conventional 2D colony formation assays [41, 42].
BV6 reduced basal clonogenic survival of non-irradiated
3D cultured cells and increased radiation sensitivity of all
three lines investigated (Fig. 4). The most prominent
radiation sensitization effect was observed in HT-29 cells
which nicely corresponded to the pronounced increased
numbers of DNA DSBs upon BV6 treatment. Apoptosis
induction was most prominent in SW480 cells. In line
with that, studies conducted by Qin et al. and Huerta
et al. reported on radiosensitization of esophageal car-
cinoma cells by the compound LCL161 [43], while
the compound JP-1201 was shown to sensitize HT-29
Fig. 7 cIAP1 and XIAP knockdown radiosensitizes colorectal cancer cells. Single cells from knockdown cell cultures were plated in a 3D
extracellular matrix and irradiated with 0, 2, 4 or 6 Gy (single doses) 24 h thereafter. Colonies with more than 50 cells were counted
microscopically 6–7 days after plating. a Typical 3D colony formation of non-irradiated (0 Gy) or irradiated (2 Gy) mock-treated (mock) or cIAP1/
XIAP depleted (cIAP1+X si) cell cultures 6–7 days after plating (bar, 200 μm). b Plating efficiency of 3D grown mock, control siRNA (co), cIAP1
siRNA (cIAP1), XIAP siRNA (X) and cIAP1/XIAP (cIAP1+X) siRNA transfected cells was determined and normalized to control siRNA (co) treated cells.
(means ± SD; n ≥3). c For measurement of 3D radiation survival, indicated knockdown cell cultures were irradiated (0–6 Gy, single dose) and
survival fractions relative to non-irradiated controls were calculated. Curves were fitted according to the linear quadratic model (means ± SD;
n ≥3; *P <0.05; **P <0.01; Student’s t-test in comparison to control (co) siRNA treatment)
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colorectal carcinoma cells in vitro and in a SCID mouse
xenograft model in conjunction with enhanced Poly(-
ADP-ribose) polymerase-1 (PARP-1) cleavage [43]. Not-
ably, these studies also analyzed the impact of SMAC
mimetic treatment on DNA damage response showing
elevated numbers of radiation-induced γH2AX-positive
nuclear foci. These results thus support our observations
on a hampered DNA repair mediated by SMAC mimetics.
Previous own data further revealed 3D radiosensitization
in a panel of colorectal cancer cells upon siRNA-mediated
attenuation of XIAP and/or Survivin [28] in line with an
increased γH2AX foci detection following single XIAP
and Survivin or double knockdown (unpublished results).
To confirm the involvement of cIAP1 and XIAP in the
modulation of DNA damage response, we here analyzed
SW480 and HCT-15 radiation responses in the presence
of siRNA targeting these proteins (Fig. 6). Irradiation of
single cIAP1 or XIAP knockdown cells significantly
increased γH2AX- and 53BP1-positive foci at 24 h while
double knockdown of cIAP1 and XIAP only marginally
further increased the number of residual foci. These data
support our hypothesis of the involvement of IAPs in
DNA DSB repair mechanisms, which has been proposed
for Survivin before [29, 44]. Mechanistically, Survivin
physically interacts with members of the DNA repair
machinery, including DNA-dependent protein kinase,
catalytic subunit (DNA-PKCS) and regulates DNA PKcs
catalytic activity in SW480 colorectal cancer cells [29].
Here, we observed a hampered DNA damage repair upon
SMAC mimetic-induced degradation of cIAP1 and XIAP,
while Survivin expression was not significantly affected
(Fig. 5). These results suggest an impact of additional
members of the IAP family on DNA damage repair, stres-
sing the significance of anti-IAP strategies to improve
radiation therapy outcome. The underlying mechanism(s)
on a cIAP1- and XIAP-mediated modulation of radiation-
induced DSB repair, however, remain elusive and require
further investigations.
In summary, our findings support the notion that BV6
mediated degradation of XIAP and cIAP1 results in
radiosensitization of colorectal cancer cells via increased
apoptosis and impaired DNA DSB repair.
Conclusion
Intervention of IAP function with SMAC mimetic com-
pounds emerges as a promising strategy to enhance radi-
ation sensitivity of cancer cells. In the present study, the
SMAC mimetic BV6 substantially increased 3D radiation
response of three human colorectal cancer cell lines by
degradation of cIAP1 and XIAP, thereby enhancing
irradiation-induced apoptosis and hampering DNA DSB
repair. Thus, BV6 may represent a molecular compound
to improve multimodal therapeutic outcome of colorec-
tal cancer.
Additional file
Additional file 1: Figure S1. Treatment with BV6 increased radiation-
induced DNA damage. SW480, HT-29 and HCT-15 colorectal carcinoma
cell lines were treated either with DMSO as a control or with 4 μM BV6
4 h before irradiation. Immunofluorescence staining for γH2AX in red
(A) or 53BP1 in green (B) was accomplished 24 h after irradiation with
0/2 Gy and nuclei were counterstained with DAPI. Photographs show
representative images of nuclear foci of indicated conditions obtained
with an AxioImager Z1 microscope equipped with AxioVision 4.6 software
(Carl Zeiss). Scale bar, 5 μm. (PPT 4679 kb)
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
SH, JO and SR performed and analyzed the experiments. SH prepared the
manuscript. SF, RF and CF participated in the design of the study and
revised the manuscript critically. CR and FR supervised the analysis, and
contributed substantially in preparing the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank D. Vucic (Genentech Inc., South San Francisco, CA, USA) for
providing BV6 SMAC mimetic. This study was supported by the German
Federal Ministry of Education and Research (BMBF; m4 cluster of excellence:
16EX1021J, GREWIS: 02NUK017F), the German Research Foundation (DFG
Graduate school 1657) and by a Joint Funding Grant within the German
Cancer Consortium (DKTK), which is funded as one of the National German
Health Centers by the BMBF.
Author details
1Department of Radiotherapy and Oncology, Goethe University Frankfurt,
Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. 2Institute for
Experimental Cancer Research in Pediatrics, Goethe University Frankfurt,
Komturstr. 3a, 60528 Frankfurt am Main, Germany. 3German Cancer Research
Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
4German Cancer Consortium (DKTK) partner site: Frankfurt, Im Neuenheimer
Feld 280, 69120 Heidelberg, Germany.
Received: 17 March 2015 Accepted: 10 September 2015
References
1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence,
mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22:191–7.
2. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al.
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N
Engl J Med. 2004;351:1731–40.
3. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al.
Preoperative versus postoperative chemoradiotherapy for locally advanced
rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III
trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.
4. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with
targeted drugs. Nat Rev Cancer. 2011;11:239–53.
5. Fulda S. Targeting IAP proteins in combination with radiotherapy. Radiat
Oncol. 2015;10:105.
6. Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug
development in oncology. Onco Targets Ther. 2013;9:1285–304.
7. Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al.
Survivin - biology and potential as a therapeutic target in oncology.
Onco Targets Ther. 2013;6:1453–62.
8. Rodel F, Sprenger T, Kaina B, Liersch T, Rodel C, Fulda S, et al. Survivin as a
prognostic/predictive marker and molecular target in cancer therapy. Curr
Med Chem. 2012;19:3679–88.
9. Carmena M, Wheelock M, Funabiki H, Earnshaw WC. The chromosomal
passenger complex (CPC): from easy rider to the godfather of mitosis. Nat
Rev Mol Cell Biol. 2012;13:789–803.
10. Sprenger T, Rodel F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K, et
al. Failure of downregulation of survivin following neoadjuvant
Hehlgans et al. Radiation Oncology  (2015) 10:198 Page 10 of 11
radiochemotherapy in rectal cancer is associated with distant metastases
and shortened survival. Clin Cancer Res. 2011;17:1623–31.
11. Flanagan L, Kehoe J, Fay J, Bacon O, Lindner AU, Kay EW, et al. High levels
of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio
chemotherapy resistance in rectal cancer. Radiat Oncol. 2015;10:131.
12. Srinivasula SM, Ashwell JD. IAPs: what’s in a name? Mol Cell. 2008;30:123–35.
13. Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a
critical death resistance regulator and therapeutic target for personalized
cancer therapy. Front Oncol. 2014;4:197.
14. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG.
IAP-targeted therapies for cancer. Oncogene. 2008;27:6252–75.
15. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg
P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB
activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669–81.
16. Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a post-translational
modification at the edge of life and death. Nat Rev Mol Cell Biol.
2011;12:439–52.
17. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis
of apoptotic activation by Smac/DIABLO. Nature. 2000;406:855–62.
18. Samuel T, Welsh K, Lober T, Togo SH, Zapata JM, Reed JC. Distinct BIR
domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis
factor receptor-associated factor 2 and second mitochondrial activator of
caspases. J Biol Chem. 2006;281:1080–90.
19. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine
TNFalpha signaling renders human cancer cells susceptible to Smac-
mimetic-induced apoptosis. Cancer Cell. 2007;12:445–56.
20. Bake V, Roesler S, Eckhardt I, Belz K, Fulda S. Synergistic interaction of Smac
mimetic and IFNalpha to trigger apoptosis in acute myeloid leukemia cells.
Cancer Lett. 2014;355:224–31.
21. Belz K, Schoeneberger H, Wehner S, Weigert A, Bonig H, Klingebiel T, et al.
Smac mimetic and glucocorticoids synergize to induce apoptosis in
childhood ALL by promoting ripoptosome assembly. Blood.
2014;124:240–50.
22. Chromik J, Safferthal C, Serve H, Fulda S. Smac mimetic primes
apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced
cell death by triggering necroptosis. Cancer Lett. 2014;344:101–9.
23. Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, et al.
NF-kappaB is required for Smac mimetic-mediated sensitization of
glioblastoma cells for gamma-irradiation-induced apoptosis. Mol Cancer
Ther. 2011;10:1867–75.
24. O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al.
Characterization of the p53 tumor suppressor pathway in cell lines of the
National Cancer Institute anticancer drug screen and correlations with the
growth-inhibitory potency of 123 anticancer agents. Cancer Res.
1997;57:4285–300.
25. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et
al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A.
1990;87:7555–9.
26. Liu Y, Bodmer WF. Analysis of P53 mutations and their expression in 56
colorectal cancer cell lines. Proc Natl Acad Sci U S A. 2006;103:976–81.
27. Dupoux A, Cartier J, Cathelin S, Filomenko R, Solary E, Dubrez-Daloz L.
cIAP1-dependent TRAF2 degradation regulates the differentiation of
monocytes into macrophages and their response to CD40 ligand. Blood.
2009;113:175–85.
28. Hehlgans S, Petraki C, Reichert S, Cordes N, Rodel C, Rodel F. Double
targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal
tumor cells and decreases migration. Radiother Oncol. 2013;108:32–9.
29. Reichert S, Rodel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, et al.
Survivin inhibition and DNA double-strand break repair: a molecular
mechanism to overcome radioresistance in glioblastoma. Radiother Oncol.
2011;101:51–8.
30. Eke I, Deuse Y, Hehlgans S, Gurtner K, Krause M, Baumann M, et al.
beta(1)Integrin/FAK/cortactin signaling is essential for human head and
neck cancer resistance to radiotherapy. J Clin Invest. 2012;122:1529–40.
31. Hehlgans S, Eke I, Cordes N. Targeting FAK radiosensitizes 3-dimensional
grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling. Int
J Radiat Oncol Biol Phys. 2012;83:e669–676.
32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144:646–74.
33. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M,
et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing
intracellular cell death complex differentially regulated by cFLIP isoforms.
Mol Cell. 2011;43:449–63.
34. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The
Ripoptosome, a signaling platform that assembles in response to genotoxic
stress and loss of IAPs. Mol Cell. 2011;43:432–48.
35. Lauber K, Ernst A, Orth M, Herrmann M, Belka C. Dying cell clearance and its
impact on the outcome of tumor radiotherapy. Front Oncol. 2012;2:116.
36. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour
Biol. 2010;31:363–72.
37. Ohnishi K, Nagata Y, Takahashi A, Taniguchi S, Ohnishi T. Effective
enhancement of X-ray-induced apoptosis in human cancer cells with
mutated p53 by siRNA targeting XIAP. Oncol Rep. 2008;20:57–61.
38. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of
cultured Chinese hamster cells. Radiat Res. 1966;29:450–74.
39. Stadel D, Cristofanon S, Abhari BA, Deshayes K, Zobel K, Vucic D, et al.
Requirement of nuclear factor kappaB for Smac mimetic-mediated
sensitization of pancreatic carcinoma cells for gemcitabine-induced
apoptosis. Neoplasia. 2011;13:1162–70.
40. Yang D, Zhao Y, Li AY, Wang S, Wang G, Sun Y. Smac-mimetic compound
SM-164 induces radiosensitization in breast cancer cells through activation
of caspases and induction of apoptosis. Breast Cancer Res Treat.
2012;133:189–99.
41. Eke I, Schneider L, Forster C, Zips D, Kunz-Schughart LA, Cordes N. EGFR/JIP-
4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of
squamous cell carcinoma cells. Cancer Res. 2013;73:297–306.
42. Lee J, Cuddihy MJ, Kotov NA. Three-dimensional cell culture matrices: state
of the art. Tissue Eng Part B Rev. 2008;14:61–86.
43. Qin Q, Zuo Y, Yang X, Lu J, Zhan L, Xu L, et al. Smac mimetic compound
LCL161 sensitizes esophageal carcinoma cells to radiotherapy by
inhibiting the expression of inhibitor of apoptosis protein. Tumour Biol.
2014;35:2565–74.
44. Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, et al.
Survivin enhances radiation resistance in primary human glioblastoma cells
via caspase-independent mechanisms. Oncogene. 2004;23:7494–506.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hehlgans et al. Radiation Oncology  (2015) 10:198 Page 11 of 11
